Chronic Cough Market Size Report (Drug Class, Route of Administration) to Grow at 7.8% CAGR During 2020-2027

The Insight Partners published latest research report on "Chronic Cough Market Size Report, Growth, Trends, Demand & Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Distribution Channel; and Geography”, the global market size is projected to reach USD 9,854.8 million by 2027 from USD 5,430.0 million in 2019. The market is estimated to grow with a CAGR of 7.8% from 2020 to 2027.

Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00011584

Growth Strategies by the Key Players Operating in the Chronic Cough Market:

Jan-2019: Mylan N.V. (announced the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc. The Cold-EEZE family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the U.S.: North America

Dec-2019: Bayer’s P2X3 receptor antagonist shows promise for chronic cough.: North America

Nov-2018: Theravance Biopharma, Inc. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for YUPELRITM inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US: North America

Oct-2018: Cipla Medpro South Africa (Pty) Ltd has completed the acquisition of 100 per cent stake in South African firm Mirren. As part of the acquisition, the Company got access to 4 key OTC brands Coryx and Broncol in the Cough & Cold segment, Tensopyn in Pain management and Ultimag, a unique Mg & Zinc Supplement: Middle East & Africa

Nov-2018: Aurobindo Pharma Ltd has acquired a product under development and related assets from Australia-based Advent Pharmaceuticals Pty. Ltd. Melbourne-based Advent Pharmaceuticals is a specialty research and development company, focused on generic inhaled products: Asia Pacific

Chronic cough is caused due to respiratory disorders, or can been seen due to chronic illness such as cancer, and medication. Factors such as of rising incidences of chronic cough and growing product developments to treat chronic cough are expected to drive the growth of the market. On the other hand, product recall is the major factor, which is likely to affect the market growth negatively during the forecast period.

The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as product launches. Whereas, the inorganic strategies such as partnership, and collaborations, were widely seen in the chronic cough market. Majority of the market leaders are involved in inorganic activities such as merger and acquisition in order to improve their performance and consolidate market position.

Directly Purchase Premium Copy of Chronic Cough Market Growth Report (2020-2027) at: https://www.theinsightpartners.com/buy/TIPRE00011584

Global Chronic Cough Market Share Report, Segmentations, Regional & Country Scope:

Browse key market insights spread across 180 pages with 72 list of tables & 72 list of figures from the report, "Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, and Other Drug Class); Route of Administration (Oral, Injections, Inhalation, Other and Route of Administration); Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy); and Geography" in detail along with the table of contents: https://www.theinsightpartners.com/reports/chronic-cough-market

Older people are more prone to have a chronic cough, and the growing age is the prime factors of decreased immunity. The degeneration of the organs and healthy tissues due to age factor invites several health conditions. Chronic cough is one of the common health conditions seen among older people. The respiratory system starts degenerating as the age progresses. Therefore, the chances of suffering from respiratory infections, such as pneumonia     and the flu increases in older people.

As developed and developing countries are witnessing a decreased death rate, there is increase in the number of geriatric population across the world. The developments in the healthcare industry have enhanced public health resulting in increased life expectancy. For instance, countries such as the US, Canada, the UK, Spain, and Japan are experiencing a significant rise in geriatric population; whereas, countries such as China, India, and South Korea have already witnessed a raise in the number of older population. According to the World Health Organization data for 2018, it is estimated that by 2050 the world’s geriatric population will reach 2 billion from 900 million in 2015. It is also estimated that China will have ~120 million people above the age of 80 years, and there will be nearly 434 million people worldwide. Additionally, it is expected that by 2050, 80% of older people will live in low and middle income countries. Therefore, the growing geriatric population is likely to demand more chronic cough treatments during the forecast period.

The universities are engaged in research work for the development of new drugs to cure chronic cough. For instance, in February 2020, the results of two clinical trials phases for a new drug, Gefapixant were releases. The researchers at the University of Manchester developed Gefapixant. The pharmaceutical market leader Merck & Co., Inc. (MSD) funded the clinical trials, in which the results showed that a dose of 7.5 mg reduced the cough by 52%, 20mg by 52%, and 50mg by 67% from baseline. The drug targets P2X3 receptors in the nerves that control coughing. Therefore, the developments by the pharmaceutical companies to treat chronic cough are likely to support the market growth during the forecast period.

The American College of Chest Physicians, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Dubai Health Authority, European Respiratory Society, and Japanese Respiratory Society are among the essential secondary sources refereed to while preparing this report.

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Cough and Cold Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Cough Syrup Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Cough Suppressant Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis

Cough Suppressants Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Cough and Cold Preparations Market Forecast to 2028 - COVID-19 Impact and Global Analysis

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com 

Phone: +1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/chronic-cough-market